The Latest Breaking News from FDA

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson’s (NYSE:JNJ) Simponi (golimumab) for children with moderately to severely active ulcerative colitis (UC) who weigh at least 15 kg.

Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading higher on Wednesday, with apparently no news to justify the movement.

Kroger issues urgent recall of pasta salads sold in 30 U.S. states due to potential Listeria contamination, prompting health warnings and consumer alerts.

We all glance at calories and maybe check sugar, but most of us miss deep insights lurking on food labels. For shoppers aiming to eat smarter—especially with allergies, diet goals, or health conditions—those hidden metrics matter. By learning which seven things to always check, you’ll dodge misleading claims, spot hidden…

On September 22, 2025, President Donald Trump released a statement suggesting that Tylenol was linked to an increased risk of autism when used by pregnant mothers. He urged pregnant women to stop taking the drug. “Don’t take Tylenol,” Trump said. “Fight like hell not to take it.” On the same…

A top U.S. health official's call to split the measles-mumps-rubella (MMR) vaccine into separate shots sparked strong pushback from Merck Co., Inc. (NYSE:MRK) and medical experts, who said such a move lacks scientific justification and could undermine immunization efforts.

Spruce Biosciences' stock surged to record highs after it received an FDA breakthrough designation for the TA-ERT candidate to treat a rare genetic disease.

Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in autoimmune diseases showed encouraging signs.

Envoy Medical Inc. (NASDAQ:COCH) announced on Tuesday that it has received U.S. Food and Drug Administration (FDA) approval to expand its pivotal clinical trial for the fully implanted Acclaim cochlear implant to the final stage, based on promising three-month data from the first 10 patients.

Spruce Biosciences Inc. (NASDAQ:SPRB) jumped to $175.00 during after-hours trading on Monday, up 34.20% or $44.60 from its closing price.

Whether you love them or avoid them, genetically modified fruits—better known as GMOs—have become impossible to ignore. From apples that don’t brown to papayas that resist disease, GMO fruit has quietly made its way onto grocery store shelves around the world. Yet confusion remains high, and misinformation spreads faster than…